COOPER COMPANIES 2026: Revenue $1.07B, Net income $432.8M, EPS $2.24— 10-Q Summary
Cooper Companies reported Q3 2026 revenue of $1.07B, flat YoY, but net income rose 340.3% to $432.8M and EPS increased 357.1% to $2.24. Growth was driven by CooperVision and CooperSurgical, with consolidated net sales up 5% YTD. The company faced mixed results in the Americas and litigation accruals at CooperSurgical.
How this was made
The 30-second read
Why it matters
The earnings beat on net income and EPS could trigger short‑term buying, while flat revenue and inventory concerns may temper longer‑term optimism.
Market read
Earnings release provides fresh data for traders; the profit surge is the primary catalyst.
What to watch
Litigation accruals for recalled embryo culture media may pose future cost risks.
Background
Cooper Companies (COO) is a medical device firm with two main divisions: CooperVision (contact lenses) and CooperSurgical (fertility products).
Ticker impact
Cooper Companies reported Q3 2026 results with revenue flat at $1.07B and net income jumping 340% to $432.8M.
Potential price rise of 3‑5% in after‑hours trading.
Net income surge and EPS beat suggest strong operating performance, likely to attract buying.
Market effects
Positive earnings may lift the ophthalmic devices and fertility services subsectors.
U.S. healthcare stocks could see modest gains.
Limited to U.S. and international investors in medical device space.
Counterpoint
The flat revenue and inventory issues in the Americas could signal underlying demand weakness.
Key entities
- divisionCooperVision
Contact lens segment driving lens sales growth.
- divisionCooperSurgical
Fertility services segment with litigation accruals.
